文献速递心力衰竭与心肌病

恩格列净对射血分数降低心衰患者血流动力学的影响

Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction.
PubMed 文献 · J Am Coll Cardiol · 2020-01-01

这项双盲安慰剂对照随机试验纳入70例射血分数降低心衰患者,评估恩格列净10 mg每日一次治疗12周对静息及运动时中心血流动力学的影响。主要终点峰值运动时肺毛细血管楔压与心脏指数比值无显著改变,但全运动负荷范围内肺毛细血管楔压显著降低。

要点

  • 恩格列净10 mg治疗12周未显著改善峰值运动时PCWP/CI比值。
  • 全运动负荷范围内肺毛细血管楔压较安慰剂显著降低。
  • 心脏指数在静息或运动时均无显著改善。

核心结论

  • 在稳定期射血分数降低心衰患者中,恩格列净治疗12周较安慰剂降低肺毛细血管楔压,但未显著改善心脏指数或静息及运动时PCWP/CI。

研究设计与样本

  • 研究者发起的双盲安慰剂对照随机试验,2018年3月6日至2019年9月10日纳入70例射血分数降低心衰患者。
  • 患者随机接受恩格列净10 mg或匹配安慰剂每日一次,在指南指导心衰治疗基础上治疗12周。
  • 主要终点为12周后峰值运动时肺毛细血管楔压与心脏指数比值。
  • 患者在基线和12周随访时接受静息及运动时右心导管检查。

主要发现

  • 患者平均年龄57岁,平均左心室射血分数26%,12例(17%)合并2型糖尿病。
  • 峰值运动时PCWP/CI的治疗效应无统计学意义(-0.13 mm Hg/l/min/m2;95%CI:-1.60至1.34 mm Hg/l/min/m2;p=0.86)。
  • 考虑全运动负荷范围的血流动力学,恩格列净显著降低PCWP(-2.40 mm Hg;95%CI:-3.96至-0.84 mm Hg;p=0.003)。
  • 心脏指数无显著改变(-0.09 l/min/m2;95%CI:-0.14至0.32 l/min/m2;p=0.448)。
  • 上述结果在合并与不合并2型糖尿病的患者中一致。

临床怎么用

  • 恩格列净可能通过降低运动时肺毛细血管楔压改善心衰患者血流动力学,但未显著提高心脏指数。
  • 临床决策应结合指南指导心衰治疗,不应仅依据本研究中血流动力学次要终点调整用药。

局限性

  • 样本量较小(70例),可能不足以检测峰值运动时PCWP/CI的微小差异。
  • 研究仅评估恩格列净10 mg治疗12周,不能推断其他剂量或更长疗程的效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inhibition of the sodium-glucose cotransporter-2 (SGLT2i) improves outcomes in patients with heart failure (HF) and reduced ejection fraction (HFrEF), but the mechanism by which they improve outcomes remains unclear. OBJECTIVES: This study aimed to investigate the effects of sodium-glucose cotransporter-2 inhibitor empagliflozin on central hemodynamics in patients with HF and HFrEF. METHODS: This investigator-initiated, double-blinded, placebo-controlled, randomized trial enrolled 70 patients with HFrEF from March 6, 2018, to September 10, 2019. Patients were assigned to empagliflozin of 10 mg or matching placebo once daily on guideline-driven HF therapy for 12 weeks. The primary outcome was ratio of pulmonary capillary wedge pressure (PCWP) to cardiac index (CI) at peak exercise after 12 weeks. Patients underwent right-heart catheterization at rest and during exercise at baseline and 12-week follow-up. RESULTS: Patients with HFrEF, mean age of 57 years, mean left-ventricular ejection fraction, 26%, and 12 (17%) with type 2 diabetes mellitus were randomized. There was no significant treatment effect on peak PCWP/CI (-0.13 mm Hg/l/min/m2; 95% confidence interval: -1.60 to 1.34 mm Hg/l/min/m2; p = 0.86). Considering hemodynamics over the full range of exercise loads, PCWP was significantly reduced (-2.40 mm Hg; 95% confidence interval: -3.96 to -0.84 mm Hg; p = 0.003), but not CI (-0.09 l/min/m2; 95% confidence interval: -0.14 to 0.32 l/min/m2; p = 0.448) by empagliflozin. This was consistent among patients with and without type 2 diabetes. CONCLUSIONS: Among patients with stable HFrEF, empagliflozin for 12 weeks reduced PCWP compared with placebo. There was no significant improvement in neither CI nor PCWP/CI at rest or exercise.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Omar M, Jensen J, Frederiksen PH, et al. Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction. J Am Coll Cardiol. 2020. PMID: 33272368. doi:10.1016/j.jacc.2020.10.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。